Clinical Trial · NCT03418818

A Prospective Study of Hypoxia Imaging in Patients With Soft Tissue Sarcoma Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Combination With MRI

Overview

This is a dual arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans. FAZA PET/MRI will be used to measure hypoxia in sarcoma tissues and will occur for: Arm A: before neo-adjuvant radiation/chemotherapy treatment; Arm B: before surgery (optional). After the FAZA PET/MRI scan, patients will be followed up via telephone, 48 hours after the scan, to see if there are any side effects due to FAZA. Up to 20 patients enrolled in Arm B will receive pimonidazole approximately 16-20 hours before surgery.

Sponsor

University Health Network, Toronto

Phase

N/A

Contacts

David Shultz, MD

david.shultz@rmp.uhn.ca

416-946-4501 ext 2127

ClinicalTrials.gov

NCT03418818

Drug / Compound

Isotope(s):
Target(s):